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Much work has been done on adriamycin-loaded albumin microspheres (Alb-MS) for chemoem- 
bolization [1-4], the rationale being that site-specific drug delivery may increase the therapeutic 
efficacy of the drug. Alb-Ms are being investigated because of their biocompatibility and because 
the degradation products of these microspheres are non-toxic. However, these microspheres have 
some disadvantages (i.e. drug loading during the microsphere preparation, low payloads, large 
burst effects). These disadvantages can be overcome by the incorporation of heparin (a highly 
negatively charged mucopolysaccharide). Albumin-heparin microspheres were prepared (i) by 
crosslinking of soluble albumin and heparin first using 1-ethyl-3-(3-dimethylaminopro- 
pyl)carbodiimide (EDC) and subsequently glutaraldehyde (Alb-Hep-MS) and (ii) by crosslinking 
a preformed soluble conjugate of heparin and albumin with glutaraldehyde (Alb-Hep-Conj-MS). 
Albumin-heparin microspheres could be loaded with adriamycin after microsphere preparation 
giving payloads of 15-30%. Preliminary in vitro adriamycin release xperiments showed that Alb- 
Hep-Conj-MS exhibit sustained release properties. Furthermore ion-exchange properties could 
be observed both with Alb-Hep-MS and Alb-Hep-Conj-MS. In vitro and in vivo toxicity experi- 
ments with Alb-Hep-MS showed no adverse ffects. 
INTRODUCTION 
Since albumin microspheres (Alb-MS) were 
first described as possible drug delivery devices 
[5 ], many different types of drugs (i.e. peptides 
[6], steroids [7,8] and low molecular weight, 
water-soluble compounds [9 ] have been incor- 
porated. Among the drugs incorporated, cyto- 
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static agents (i.e. mercaptopurine [5], 5-fluo- 
rouracil [8], mitomycin C [ 10 ], and adriamycin 
[ 1-4 ] ) take an important place. 
In the past much work has been done on the 
preparation and application of adriamycin 
loaded albumin microspheres (Adx-Alb-MS) 
[ 1,3,4 ]. Adriamycin is an anthracycline anti- 
biotic which is widely used in cancer chemo- 
therapy. This cytostatic agent however, exerts 
high cardiotoxicity upon intravenous bolus in- 
jection, which is a major drawback in the appli- 
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cation of this drug. This may be overcome by 
the incorporation of the drug in microparticu- 
late carriers (e.g. Alb-MS), which can be used 
for chemoembolization. Chemoembolization 
refers to the intra-arterial coadministration f 
drugs and vascular occlusive devices to treat 
cancer. The rationale is that the administra- 
tion of drug loaded particles of the requisite size 
(15-60 ttm) either causes tumour infarction by 
occlusion or induces transient ischemia within 
the tumour vasculature, whereupon the en- 
trapped rug can be released locally. Moreover, 
tissue permeability is increased ue to anoxia, 
allowing the drug to permeate into the tissue 
more easily [11 ]. 
In general Adx-Alb-MS are prepared as fol- 
lows. An aqueous solution of albumin which also 
contains adriamycin is added to an organic 
phase (i.e. olive oil, cottonseed oil, or a mixture 
of cottonseed oil with petroleum ether). A 
water-in-oil emulsion is being formed by me- 
chanical stirring or by sonification. Stabiliza- 
tion of the Adx-Alb-MS is then carried out 
either by heat stabilization or by chemical 
crosslinking using gluraraldehyde, formalde- 
hyde or 2,3-butadione as crosslinking agents 
[1,3,4]. 
The use of Adx-Alb-MS for the release of 
adriamycin has some drawbacks. The prepara- 
tion methods afford only low payloads (1-10%). 
Furthermore, adriamycin may react with the 
crosslinker during the stabilization process. 
Adriamycin may also decompose when the 
microspheres are stabilized at high tempera- 
tures. The microspheres prepared are some- 
what hydrophobic and surfactants are needed 
to resuspend them in aqueous olutions. An- 
other problem is the large burst effect usually 
observed with Adx-Alb-MS. 
Longo and Goldberg have developed a method 
to prepare hydrophilic albumin microspheres 
[2]. A concentrated solution of high molecular 
weight polymer in an organic solvent instead of 
oil was used as the hydrophobic (organic) 
phase. Glutaraldehyde is dissolved in the or- 
ganic phase and reacts mainly at the surface of 
the Alb-MS, yielding a relatively high surface 
concentration f unreacted aldehyde groups. In 
this way relatively hydrophilic microspheres are 
obtained. The authors claim that these micro- 
spheres can be loaded with adriamycin after the 
preparation and that payloads of about 18% can 
be reached. 
In general the in vitro release of adriamycin 
from these monolithic albumin microspheres is 
considered to be biphasic. An initial large and 
fast release (i.e. the burst effect), is followed by 
a much slower, first-order release [12 ]. During 
the first phase a large amount of the drug may 
be released within a few minutes to hours. Some 
authors, however, propose triphasic zero-order 
kinetics [13,14]. 
Some of the disadvantages mentioned above 
may be overcome by incorporating negatively 
charged polymers into the albumin micro- 
spheres. Longo et al. [15] used a combination 
ofpoly (~-L-glutamic acid) and albumin in their 
microspheres. Adriamycin loading after prepa- 
ration gave surprisingly high payloads up to 40% 
and more (instead of 16% for unmodified al- 
bumin microspheres). Willmott et al. [16] 
modified albumin microspheres bythe addition 
of poly (fl-L-aspartic acid). Drug loading during 
the preparation process resulted in a payload of 
4% (1% for unmodified albumin microspheres). 
In order to obtain improved carriers for the 
delivery of cytostatic agents, we have prepared 
microspheres which are made from albumin and 
heparin (Alb-Hep-MS). These microspheres 
have been synthesized by techniques similar to 
the preparation ofalbumin microspheres ither 
starting with an aqueous mixture of albumin 
and heparin followed by stabilization with 1- 
ethyl-3- (3-dimethylaminopropyl) carbodiim- 
ide (EDC) and glutaraldehyde, r spectively, or
by use of preformed soluble albumin-heparin 
conjugates [17], which are stabilized with glu- 
taraldehyde. In this way hydrophilic, biode- 
gradable microspheres composed of endoge- 
nous materials are obtained. Heparin is highly 
negatively charged at physiological conditions 
due to carboxylic acid, sulphate and sulpha- 
mate groups. Thus strong ionic interactions 
with positively charged rugs like adriamycin 
are possible [18]. This also may provide high 
payloads for such drugs and prolong the release. 
The loading of the microspheres can be carried 
out after the microspheres have been prepared. 
In principle Alb-Hep-MS can also be loaded 
with other drugs of higher molecular weight by 
a swelling-deswelling process. The prepara- 
tion, characterization a d release properties of 
Alb-Hep-MS loaded with adriamycin will be 
discussed in this paper. The results are com- 
pared with these obtained with Alb-MS. 
MATERIALS AND METHODS 
Reagents 
Human serum albumin was obtained from the 
Central Laboratory of the Dutch Red Cross 
Blood Transfusion Service, Amsterdam, The 
Netherlands. Heparin from porcine intestinal 
mucosa was obtained from Diosynth, Oss, The 
Netherlands. Two different batches were used, 
both with a specific activity of 165 IU/mg as 
indicated by the manufacturers. Cibracon blue 
sepharose (CBS) and diethylaminoethyl se- 
pharose 4B (DEAE) were obtained from Phar- 
macia Fine Chemicals, Uppsala, Sweden. EDC 
used in microsphere preparation (double cross- 
linking technique) and highly refined olive oil 
were both obtained from Sigma Chemical Com- 
pany, St. Louis, MO, U.S.A. EDC used for the 
conjugate synthesis, glutaraldehyde (25% 
aqueous olution), and the solvents and other 
chemicals used, were all obtained from Merck- 
Schuchardt, Hohenbrunn, West-Germany. 
Adriamycin was a kind gift from Prof. Dr. F. 
Arcamone, Farmitalia, Milan, Italy. Polycar- 
bonate membrane filters (8 pm) were obtained 
from Nuclepore, Pleasanton, USA. BD2F1 mice 
and WAG/Rij rats, bred under SPF conditions, 
were obtained from the Animal Department of
the Netherlands Cancer Institute, Amsterdam, 
The Netherlands. 
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Synthesis, purification and characterization 
of soluble conjugates of albumin and 
heparin 
The synthesis of the albumin-heparin con- 
jugate was carried out by the slightly modified 
method of Hennink et al. [17]. Albumin (12.5 
g) and heparin (3.75 g) were dissolved in 175 
ml of water. This solution was adjusted to pH 
5.0 with HC1 (0.2 M). During the addition of 
HC1, a precipitate was formed. This precipitate 
dissolved almost completely within 45 minutes. 
A solution of 1.24 g EDC was added ropwise to 
the reaction mixture over a period of 4 hours at 
room temperature. Thirty minutes after the ad- 
dition of EDC, the pH was adjusted to 7.6 with 
NaOH (1 M) and the mixture was gently stirred 
for 20 h at 4 ° C. Finally the solution was di- 
alyzed twice against 0.025 M Tris-HC1 buffer, 
pH 7.5. 
Unreacted heparin and albumin were sepa- 
rated from the albumin-heparin conjugate with 
chromatographic procedures, using a CBS col- 
umn and a DEAE column, respectively. 
The heparin content of the conjugate was de- 
termined with the slightly modified colorimet- 
ric method using Azure A as described by 
Jacques and Wollin [ 19 ]. The albumin content 
was determined using two methods, by UV/Vis 
spectroscopy at 280 nm, and by a modified biu- 
ret-method [20 ]. 
Microsphere preparation 
Albumin microspheres (Alb-MS) were pre- 
pared as described by Tomlinson et al. [12]. In 
a typical experiment 125 ml of highly refined 
olive oil was prestirred (850 rpm) in a baffled 
cell at room temperature for at least 30 min- 
utes. To this oil 0.4 ml of an albumin solution 
(150 mg dissolved in 0.6 ml isotonic buffer pH 
7.4) was added dropwise from a syringe. The 
resulting water-in-oil emulsion was stirred for 
15 minutes. Then 0.1 ml of an aqueous glutar- 
aldehyde solution (25% w/v) was added. After 
1 h stirring, 55 ml of acetone was added and 
stirring was continued for 1 minute. The micro- 
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spheres were isolated by centrifugation for 15 
minutes at 2000 rpm, followed by decanting of 
the supernatant. After resuspending the micro- 
spheres in acetone and collecting them on a 8 
/~m polycarbonate membrane filter, they were 
washed and dehydrated with acetone. In the 
case of adriamycin-loaded albumin micro- 
spheres (Adx-Alb-MS) the adriamycin was 
added to the albumin solution before 
emulsification. 
Albumin-heparin microspheres made from 
the soluble conjugate (Alb-Hep-Conj-MS) were 
prepared in a similar way as the Alb-MS. Since 
the conjugate solution was more viscous, a 
higher stirring speed (1230 rpm) was required 
to obtaine microspheres with a similar size as 
Alb-MS. The crosslinking time after glutaral- 
dehyde addition was 3.5 hours. 
Albumin-heparin microspheres (Alb-Hep- 
MS ) were also prepared from free albumin and 
heparin, using a double crosslinking technique. 
A solution (0.4 ml) of 100 mg of albumin and 
50 mg of heparin in 0.6 ml water was added 
dropwise to prestirred (850 rpm) olive oil. After 
emulsification for 15 minutes, 0.1 ml of EDC 
solution (30 mg EDC in 0.15 ml water) was 
added. After stirring for 4 h, 0.1 ml of an aqueous 
glutaraldehyde solution (25% w/v) was added 
and the emulsion was stirred for one more hour. 
Microspheres were collected and washed as de- 
scribed above. 
After the preparation, the microspheres were 
extensively washed to remove unbound mate- 
rial. This washing procedure was carried out as 
follows. The microspheres (about 100 mg) were 
ultrasonically resuspended in 5 ml ethanol. To 
this suspension 45 ml of a 4 M NaCl solution 
was added and the microspheres were gently ro- 
tated overnight at 25 ° C. The microspheres were 
then isolated by centrifugation (15 minutes, 
2600 rpm) and the supernatant was decanted. 
The microspheres were once more resuspended 
in 50 ml 4 M NaC1 solution and rotated for 30 
minutes. After centrifugation, this was re- 
peated once with a 2 M NaC1 solution and twice 
with water. The microspheres were then col- 
lected on a 8/~m polycarbonate membrane filter 
and dehydrated with acetone. 
Particle size of the microspheres 
The determination f the size and the size 
distribution of the microspheres was carried out 
using scanning electron microscopy and by us- 
ing a light microscope fitted with a calibrated 
graticule. The SEM micrographs were analyzed 
using a particle size analyzer (Carl-Zeiss TG3 ). 
Quenching of the microspheres 
Because the microspheres were crosslinked 
with glutaraldehyde, some unreacted aldehyde 
groups may be left in the matrix. To prevent 
covalent coupling of the adriamycin via its 
amine group to these aldehyde groups, micro- 
spheres were quenched with glycine. Dry 
microspheres (10 mg) were ultrasonically re- 
suspended in 0.5 ml of ethanol, after which 0.5 
ml of water was added. This suspension was 
centrifuged for 15 minutes at 2000 rpm and the 
supernatant was decanted. To the hydrated 
microspheres was added 1ml of a 10 w/v % gly- 
cine solution in water. This suspension was 
gently rotated for 20 h at 25 ° C. The suspension 
was then centrifuged for 15 minutes at 2000 
rpm, the glycine solution was decanted and the 
quenched microspheres were washed with water 
and dehydrated with acetone. 
Drug loading 
The microspheres (except for the Adx-Alb- 
MS) were loaded after preparation. In a typical 
experiment, 10 mg of microspheres were ultra- 
sonically suspended in 0.5 ml of ethanol and 0.5 
ml of water was added. After centrifugation (15 
minutes, 2000 rpm) and decanting of the su- 
pernatant, 1 ml of adriamycin solution (10 mg/ 
ml water) was added. This suspension was 
gently rotated for 20 h, at 4 ° C, blocking light. 
After collection of the microspheres, they were 
washed four times with I ml of water. The rins- 
ing water containing unbound adriamycin was 
carefully collected. After washing the micro- 
spheres were dehydrated with acetone. 
Payload determination 
Payloads (% w/w) were calculated from the 
adriamycin depletion of the loading solution and 
the adriamycin content in the rinsing water. 
These were determined by UV/Vis spectros- 
copy at 494 nm. 
In vitro release experiments 
For the in vitro release xperiments wo sys- 
tems (a batch system and a flow system) were 
used. In the batch system 5mg of microspheres, 
ultrasonically suspended in 0.5 ethanol, were 
added to 50 ml release medium (double distilled 
water, or isotonic buffer pH 7.4 containing 0.1% 
v/v Tween 80), pre-equilibrated at 37 ° C in 300 
ml bottles in a shaking bath. At different ime 
intervals, the suspension was homogenized and 
1.5 ml samples were taken. These were centri- 
fuged for 5 minutes at 1000 rpm. The adria- 
mycin content from the supernatant was deter- 
mined with UV/Vis spectroscopy at494 nm. 
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Fig. 1. Flow system for in vitro adriamycin release from 
microspheres. 
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In the flow system (Fig. 1), a glass column 
(~ = 1 cm) was filled with glass beads (1.5 ml, 
first layer), glass beads (1 ml) mixed with 5 mg 
of dry, loaded Alb-Hep-Conj-MS (second layer) 
and 1 ml of glass beads again (third layer). The 
system was equilibrated at 37°C. The flow rate 
was controlled at 13.6 ml/min. The release me- 
dium was isotonic buffer, pH 7.5. The adria- 
mycin content from the eluted buffer was de- 
termined with UV/Vis spectroscopy at 494 nm. 
In vitro toxicity of the AIb-Hep-MS 
The in vitro toxicity of the albumin-heparin 
microspheres obtained via the double cross- 
linking technique was studied using a colony 
formation assay. Cultured B16 melanotic mel- 
anoma cells ( + 75 per well) were incubated for 
6 days with 3 ml of a microsphere suspension 
(varying from 0.001 mg/ml to 10 mg/ml; n= 6; 
control: n-- 10). After 7 days the cells in the dif- 
ferent wells were counted. 
In vivo toxicity of the AIb-Hep-MS 
The in vivo toxicity of the albumin-heparin 
microspheres obtained via the double cross- 
linking technique was determined by IP admin- 
istration of microspheres into BD2F1 mice. The 
microspheres were ultrasonically resuspended 
in ethanol (75% w/v) and sterilized by 30 min- 
utes incubation. After centrifugation and de- 
canting of the ethanol, the microspheres were 
resuspended in 0.9% NaC1 solution. This sus- 
pension was IP injected in different amounts 
varying from 5.0 mg/kg to 200 mg/kg (n--6). 
In control experiments, a 0.9% NaC1 solution 
without microspheres was injected (n=10).  
The weight of the mice was monitored at dif- 
ferent ime intervals, being a first indication of 
the in vivo toxicity of the Alb-Hep-MS. 
After an inoculation period of 60 days, the 
mice were sacrificed for further histological ex- 
amination of the organs (i.e. liver, spleen, lungs, 
stomach, kidneys). A general histological stain 
(hematoxylin and eosin) was used to differen- 
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tiate cell types after fixation in 4% formol 
(buffered formaline). 
In vivo biodegradation of AIb-Hep-MS 
In 12 male WAG/Rij rats (average weight: 
300 g) a dose of 6.0 mg Alb-Hep-MS/kg rat was 
injected via the mesenteric vein into the liver. 
The same microsphere suspension was pre- 
pared as mentioned above. The rats were kept 
in a temperature-controlled room on a 12 h 
light-12 h darkness chedule in a standard rat 
cage, with tap water ad libitum. The weight of 
the rats and the level of liver-function marker 
enzymes was monitored for two weeks. After six 
weeks the animals were sacrificed for further 
examination. Liver sections were fixated using 
4% formol and stained with Giemsa-stain. 
RESULTS AND DISCUSSION 
The conjugate of albumin and heparin (Alb- 
Hep-Conj ) was prepared according to Hennink 
et al. in a yield of about 50%. The conjugate 
could be further separated in fractions with a 
low and high affinity for the DEAE column. (G. 
Engbers and J. Feijen, unpublished results). 
Table 1 shows the compositions ofthe two frac- 
TABLE1 
Composition of the albumin-heparin conjugates 
Heparin Albumin Alb/Hep b 
content" content ( mol/mol ) 
(w%) (w%) 
Low DEAE 
affinity 
fraction 
High DEAE 
affinity 
fraction 
10.0_+2.1 92.5_+2.9 c 1.56-+0.47 
92.3 -+ 3.0 d 
10.2_+1.2 93.6-+2.6 c 1.50__.0.30 
88.1 + 3.0 d 
"Colorimetric determination using Azure A. 
bMolecular weights used for this calculation were 66,000 for albu- 
min and 11,000 for heparin. 
CDetermination using a modified biuret method for protein 
determination. 
dUV/Vis spectrophotometric determination at280 nm. 
TABLE 2 
Results of microsphere preparation 
Alb-MS Alb-Hep-MS Alb-Hep-Conj- 
MS 
Stirring speed 850 850 1230 
(rpm) 
Diameter {#m) 4-25 4-30 12-80 
Yield 
conjugate synth. - - 50% 
ms-preparation 98% 94% 90% 
washing 77% 50% 76% 
Appearance brown, free- white, free- brown, free- 
flowing powder flowing powder flowing powder 
tions; the high DEAE affinity fraction was used 
for the preparation of the Alb-Hep-Conj-MS. 
The results of the microsphere preparation 
are shown in Table 2. To obtain Alb-Hep-Conj- 
MS of approximately the same size as Alb-MS 
and Alb-Hep-MS, a higher stirring speed is re- 
quired. This is due to the higher viscosity of the 
Alb-Hep-Conj solution which is used for injec- 
tion into the oil phase. Figure 2 shows that the 
Alb-Hep-Conj-MS (2c) are still larger than the 
other microspheres (2a, 2b), and have a larger 
size distribution which is also due to the higher 
viscosity of the aqueous conjugate solution. The 
sizes ofAlb-MS (2a) and Alb-Hep-MS (2b) are 
comparable, but the latter microspheres show 
partially collapsed surfaces, which may be due 
to the extraction of unbound material during 
the washing steps. The amount of material re- 
moved during washing for these Alb-Hep-MS 
was substantially higher as compared to that 
for the other microsphere preparations (Table 
2 ). The weight loss of the latter preparations is 
probably only due to the losses during the de- 
cantation and collection steps. The surfaces of 
Alb-Ms and Alb-Hep-Conj-MS were perfectly 
smooth (2a, 2c). 
Since the conjugate with the highest affinity 
for the DEAE column was used for the Alb-Hep- 
Conj-MS preparation, the composition ofthese 
microspheres is known. It can also be expected 
that the heparin is homogeneously distributed 
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Fig. 2. SEM micrographs from (a) Alb-MS and (b) Alb-Hep-Ms. 
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Fig. 2 (continued). SEM micrographs from (c) Alb-Hep-Conj-MS. 
throughout he microsphere. The composition 
of the Alb-Hep-MS is not exactly known. Also 
it is not known if the heparin or the albumin is 
located preferentially at the core or at the sur- 
face of the droplets in the water-in-oil emul- 
sion. These factors certainly influence the drug 
loading and drug release properties of the 
microspheres, and will be further investigated 
to fully understand the behaviour of these drug 
release systems. 
As can be seen from Table 3, the payloads of 
TABLE 3 
Payloads of the microspheres 
Adx-Alb-MS a Alb-MS b Alb-Hep-MS c Alb-Hep-Conj-MS a 
8% 7% 25-30% 15-20% 
aDmg loading during microsphere preparation. 
bDrug loading after micmsphere preparation, rinsing water was 
coloured up to the fourth washing step. 
CDmg loading after microsphere p paration, the microspheres 
were not rinsed with water after loading. 
dDmg loading after microsphere preparation. 
the AIb-MS and the Adx-Alb-MS were approx- 
imately the same. However, HPLC analysis of 
the drug from the Adx-Alb-MS showed that the 
major amount consisted of the aglycon-moiety 
of adriamycin, thus indicating decomposition 
of the adriamycin during the drug loading pro- 
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Fig. 3. Adriamycin release from albumin and albumin-hep- 
arin microspheres in isotonic buffer, containing 0.1% v/v 
Tween 80 and in water. Initial amount of adriamycin: Alb- 
Hep-MS: 1.2 mg; Alb-MS: 0.3 mg. - I - :  Alb-Hep-MS, 
buffer; . . . . . .  • . . . . . .  : Alb-Hep-MS, water; -[2]- :  Alb-MS, 
buffer; . . . . . .  [] . . . . . .  :Alb-MS, water. 
cess. This was not the case with the other 
microspheres, which were loaded after 
preparation. 
The drug loading of the Alb-Hep-MS and the 
Alb-Hep-Conj-MS resulted in higher payloads 
as compared to the Alb-MS. The payload of the 
Alb-Hep-MS was the highest, but it should be 
taken into account that these microspheres were 
not washed with water (to remove free drug) 
after drug loading. As can be observed from Fig. 
3, adriamycin is released from these micro- 
spheres in water. It must be concluded that the 
payload of these microspheres would have been 
reduced had these microspheres been treated 
the same way as the AIb-MS and the Alb-Hep- 
Conj-MS. In the Alb-Hep-Conj-MS, almost no 
free drug was present after drug loading, since 
the water from the washing steps after drug 
loading was colourless. 
From Fig. 3 it can be observed that the adri- 
amycin release from Alb-Hep-MS is influenced 
by the ionic strength of these release medium. 
In isotonic buffer, the amount of adriamycin re- 
leased is almost wice as high as in water. From 
this it may be concluded that the Alb-Hep-MS 
exhibit ion-exchange properties. Also, the 
amount of adriamycin released from the Adx- 
Alb-MS was much lower than the release from 
the Alb-Hep-MS. Figure 4 shows another ex- 
0.6  o 
~_ o.s. 
Q 
• 
~ 0.3- -) 
N-  0.2- 
Eg 
g~ o.1 
0.0 
0 
[ ]  
Q 
! I 
10 20 
i 
30 
time [h] 
| I 
40 50 60 
Fig. 4. Adriamycin release from albumin-heparin micro- 
spheres, prepared using double crosslinking and loaded after 
preparation• Release medium: water; at a: addition isotonic 
buffer, containing 0.1% v/v Tween 80. Initial amount of 
adriamycin: 1.2 mg. 
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ample of ion-exchange effects. After addition of 
isotonic buffer to the release medium (water) 
and thus increasing the ionic strength of the 
medium, the release of adriamycin s more than 
doubled. From Fig. 5 can be seen that adria- 
mycin release from the Alb-Hep-Conj-MS is a 
two-phase process. First there is an initial burst, 
which is followed by a slower elease in the sec- 
ond phase. This can also be observed in Fig. 6: 
an initial fast release (ca. 23% release within 
one hour) followed by a slow release (ca. 8% 
release for the next 6 hours). This release pat- 
tern is favourable compared with the release 
0.8 
0.7 
0.6 
0.5 
0.4 
0.3 
0.2 
0.1 
0.0 I 
-E  
~=- "-- ~.-~,-, .~, m ~- - - - - -=  ---~----- =, ....... ?- 
0 1 2 3 4 5 6 
time [h] 
Fig. 5. Adriamycin release from quenched and unquenched 
albumin and Alb-Hep conjugate microspheres (both loaded 
after preparation) in isotonic buffer, containing 0.1% v/v 
Tween 80. Initial amount of adriamycin: Alb-Hep-Conj- 
MS: 1.0 mg; Alb-MS: 0.35 mg. -m- :  Alb-MS, unquenched; 
...... • ...... :Alb-MS, quenched; - [~- :  Alb-Hep-Conj-MS, 
unquenched; ...... [] ..... : Alb-Hep-Conj-MS, quenched. 
5O 
40-  
" 30" 
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time [h] 
Fig. 6. Adriamycin release from albumin-heparin conju- 
gate microspheres in isotonic buffer, containing 0.1% v/v 
Tween 80, using a flow system. 
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patterns from Adx-Alb-MS and loaded Alb-MS 
and Alb-Hep-MS since in these systems, the 
major amount of adriamycin is released almost 
instantly. Administration of these adriamycin 
formulations will resemble a bolus injection. In 
the case of Alb-Hep-Conj-MS only a relatively 
small amount of adriamycin is released uring 
the first 15 minutes. This provides ufficient 
time to inject the microspheres into the target 
organ applying the principle of chemoembo- 
lization. 
From the release xperiments it can be con- 
cluded that the release of adriamycin from the 
albumin and albumin-heparin matrices de- 
pends on the way the drug is present in the ma- 
trix (Fig. 7). Part of the adriamycin in the 
microspheres will be unbound. This free drug 
will be released in buffer as well as in water and 
the release rate is controlled by the diffusion of 
the drug through the albumin-heparin matrix. 
Another part of the adriamycin has formed an 
ion complex with the negatively charged groups 
of the matrix, and will only be released if the 
ionic strength of the release medium is high 
enough. In AIb-MS and Adx-Alb-MS only a 
small amount of negatively charged groups is 
present and although Alb-MS exert some ion- 
exchange properties [21], almost no influence 
of the ionic strength of the release medium on 
the adriamycin release can be observed (Figs. 3 
and 5). The AIb-Hep-MS and the Alb-Hep- 
Conj-MS, however, are highly negatively 
charged (depending on the amount of heparin ) 
and these microspheres clearly show ion-ex- 
change properties (Figs. 3, 4 and 5). 
Finally, some of the drug will be covalently 
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Fig. 8. In vitro toxicity determined by colony formation 
assay, continuous exposure, during 6 days, of B16 melan- 
otic melanoma cells ( ± 75 ) to 3 ml Alb-Hep-MS suspen- 
sion. (1)control; (2) 10 ]lg/ml; (3) 1 #g/ml; (4)0.1 zg/  
ml; (5) 0.01 ]~g/ml; (6) 0.001 ttg/ml. 
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Fig. 9. In vivo toxicity of Alb-Hep-MS; mean body weight 
of mice after IP injection of microsphere suspension (n = 6, 
control: n=10) . - [ - ] - :  cont ro l ; -O- :  200 mg/kg ; - I - :  
100 mg/kg; -0 - :  50 mg/kg; . . . . . .  • . . . . . .  : 25 mg/kg; . . . . . .  
[] . . . . .  : 12.5 mg/kg; . . . . . .  • . . . . . .  : 5 mg/kg. 
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TABLE 4 
Plasma levels of liver-function marker enzymes [IU/1], after Alb-Hep-MS administrat ion i to rat liver (2 rats); micro- 
spheres were injected at day 1 
Enzymes ~ Day 
0 1 2 5 9 14 
I II I II I II I II I II I II 
Alk. phosph. 237 203 180 212 163 541 168 1205 1093 2173 630 757 
SGOT 50 78 183 302 79 654 51 42 28 56 49 136 
SGPT 34 263 148 263 63 502 19 11 21 26 52 
~,-GT 0 1 0 1 0 12 1 7 0 3 1 0 
LDH 385 417 636 709 698 1230 737 561 290 897 498 641 
aAlk. phosph.: alkaline phosphatase; SGOT: serum glutamate oxaloacetate ransaminase; SGPT: serum glutamate pyruvate 
transaminase; ~,-GT: y-glutamyl transferase; LDH: lactate dehydrogenase. 
bound to the matrix by the reaction of the adri- 
amycin NH2 groups with the unreacted alde- 
hyde groups. This drug will only be released by 
the degradation ofthe matrix. Quenching of the 
aldehyde groups with glycine before drug load- 
ing prevents the covalent coupling of adriamy- 
cin to the matrix. It may be expected that 
quenching of the microspheres will influence 
both drug loading and drug release. However, 
from Fig. 5 it can be observed that quenching 
with glycine has no significant effect on the 
adriamycin release from Alb-MS and Alb-Hep- 
Conj-MS. From this it can be concluded that 
the release of adriamycin is mainly due to un- 
bound and ionically bound drug. 
The results from the biocompatibility exper- 
iments of the Alb-Hep-MS are shown in Fig- 
ures 8 and 9. Figure 9 shows that the unloaded 
Alb-Hep-MS have no effect on B16 melanotic 
melanoma cells. The microspheres do not exert 
toxic effects, nor any growth-stimulating effect 
in vitro. 
Figure 9 shows the results from the in vivo 
toxicity experiments. It can be seen that the IP 
administration i  mice (even in high amounts 
of 200 mg/kg), has no significant effect on the 
growth of the mice. 
After histological examination no pathologi- 
cal alterations could be observed in any of the 
treated groups. All organs (liver, spleen, lungs, 
stomach, kidneys ) showed a normal 
appearance. 
After 60 days, incapsulated microspheres 
could be observed in the BD2F1 mice treated 
with the highest IP dose of Alb-Hep-MS. This 
indicates that the microspheres are stable. This 
was not observed in animals treated with lower 
doses. 
After i.v. administration f Alb-Hep-MS into 
the liver of rats, no significant weight loss of the 
treated animals versus controls was observed. 
Table 4 shows that there is a slight increase of 
the level of liver-function marker enzymes; 
however, this is probably due to the trauma in- 
duced by the operation and the changes are not 
irreversible, thus indicating that administra- 
tion of Alb-Hep-MS to the rat liver causes no 
irreversible damage to the liver as measured by 
the marker enzyme determination. 
Histological examination ofthe liver showed 
that after six weeks occluded microspheres still 
can be found within the portal vein system of 
the rat liver. A follow-up of these experiments 
is in progress. 
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CONCLUSIONS 
Albumin-hepar in  microspheres can be pre- 
pared by a double crossl inking technique using 
soluble a lbumin and hepar in  and by a two-step 
process. In this two-step process, f irst a soluble 
a lbumin-hepar in  conjugate is prepared,  which 
is used for the microsphere preparat ion  in the 
second step. 
A lbumin-hepar in  microspheres can be loaded 
with adr iamycin  after  the microsphere prepa-  
ration, giving a high pay load as compared  to al- 
bumin  microspheres.  The  adr iamycin  release 
f rom the A lb -Hep-Con j -MS (two-step pro- 
cess), shows a two-phase release: f irst there is 
an initial burst, followed by a slower release. The  
in vitro and in vivo exper iments  suggest the Alb- 
Hep-MS are non-toxic.  Also no in f lammatory  
react ions were induced by the A lb -Hep-MS 
after IP  administ rat ion.  Admin is t rat ion  of a 
dose of 6.0 mg/kg  into the liver of rats does not  
cause any irreversible damage to the l iver func- 
tion. The  in vivo biodegradat ion studies show 
that  the microspheres are still p resent  in the 
liver after six weeks. 
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